A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Fimasartan (Primary)
- Indications Coronary disorders
- Focus Therapeutic Use
- Acronyms FIMA-DEFER
- 10 Jun 2017 Biomarkers information updated
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2015 Planned End Date changed from 1 Jun 2013 to 1 May 2019 as reported by ClinicalTrials.gov record.